PharmaLeaders.com

News. Resources. Community.

  • Features
  • Channels
    • Biotech Channel
    • Clinical Channel
    • CME Channel
    • Compliance Channel
    • Device Channel
    • HIMSS Channel
    • Marketing Channel
    • Pharma Channel
    • R&D Channel
    • Telehealth Channel
    • Training Channel
  • Events
  • On Demand
  • White Papers
  • Vendors
    • Biotech Vendors
    • Clinical Vendors
    • CME Vendors
    • Compliance Vendors
    • Device Vendors
    • Marketing Vendors
    • Pharma Vendors
    • R&D Vendors
    • Training Vendors
  • Contributors

Eli Lilly, Incyte receive FDA approval for severe alopecia areata medicine

06/23/2022 by PharmaLeaders Aggregator

This post was originally published on this site

Olumiant is marked as the first and only systemic medicine for severe AA adult patients. It is an oral and once-daily JAK inhibitor which is available through specialty

The post Eli Lilly, Incyte receive FDA approval for severe alopecia areata medicine appeared first on Pharmaceutical Business review.

Filed Under: Industry News

  • Facebook
  • LinkedIn
  • Twitter

Choose Your Channel

Receive event announcements and special reports directly in your inbox.
  • This field is for validation purposes and should be left unchanged.

Upcoming Events

  1. Oncology at Total Health 2022

    October 20 - October 21
  2. Reuters Events: Pharma Marketing USA 2022

    November 8 - November 9
  3. Reuters Events: Pharma & Patient USA 2022

    November 8 - November 9

View All Events

  • About Us
  • Sponsorship
  • Join Our Team
  • Contact Us

Copyright © 2022 PharmaLeaders.com. All rights reserved.

Copyright © 2022 · Magazine Pro Theme on Genesis Framework · WordPress · Log in